Tom Curran

Executive Director and Chief Scientific Officer

Children's Mercy Hospital

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Tom Curran is the Executive Director and Chief Scientific Officer at Children's Mercy Hospital Adele Hall Campus in the United States. His research focuses on structural variants in rare genetic diseases, early cancer detection through innovative techniques such as liquid biopsies, and the genomic analysis of pediatric rare disease genomes. Additionally, he investigates the role of macrophages in medulloblastoma and the effects of statins on hedgehog signaling.

Articles (10)

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

Taeju Park

Assistant Professor

University of Missouri Kansas City

UNITED STATES

View details

Paul Brennan

University of Edinburgh

UNITED KINGDOM

View details

Guillaume Bourque

McGill University

CANADA

View details

Daniel Orringer

Associate Professor

NYU Langone Health

UNITED STATES

View details

Candace Savonen

Fred Hutchinson Cancer Research Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Tom Curran

Research Interests

Explore related searches

Contact this professor

About

Articles (10)

Pangenome graphs improve the analysis of structural variants in rare genetic diseases

A spectroscopic liquid biopsy for the earlier detection of multiple cancer types

Global serum profiling: an opportunity for earlier cancer detection.

Direct haplotype-resolved 5-base HiFi sequencing for genome-wide profiling of hypermethylation outliers in a rare disease cohort.

Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality.

Genomic answers for children: Dynamic analyses of >1000 pediatric rare disease genomes.

Quantitative assessment of glioblastoma phenotypes in vitro establishes cell migration as a robust readout of Crk and CrkL activity

Macrophages in SHH subgroup medulloblastoma display dynamic heterogeneity that varies with treatment modality.

A call to action: Issuing a diversity and inclusion challenge to research organizations

Statins repress hedgehog signaling in medulloblastoma with no bone toxicities

Collaborators (5)

Taeju Park

Paul Brennan

Guillaume Bourque

Daniel Orringer

Candace Savonen

Make your next move.